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The liver is the central hub for processing and maintaining homeostatic levels of dietary
nutrients especially essential amino acids such as tryptophan (Trp). Trp is required not only
to sustain protein synthesis but also as a precursor for the production of NAD,
neurotransmitters and immunosuppressive metabolites. In light of these roles of Trp
and its metabolic products, maintaining homeostatic levels of Trp is essential for health
and well-being. The liver regulates global Trp supply by the immunosuppressive enzyme
tryptophan-2,3-dioxygenase (TDO2), which degrades Trp down the kynurenine pathway
(KP). In the current study, we show that isolated primary hepatocytes when exposed to
hypoxic environments, extensively rewire their Trp metabolism by reducing constitutive
Tdo2 expression and differentially regulating other Trp pathway enzymes and
transporters. Mathematical modelling of Trp metabolism in liver cells under hypoxia
predicted decreased flux through the KP while metabolic flux through the tryptamine
branch significantly increased. In line, the model also revealed an increased accumulation
of tryptamines under hypoxia, at the expense of kynurenines. Metabolic measurements in
hypoxic hepatocytes confirmed the predicted reduction in KP metabolites as well as
accumulation of tryptamine. Tdo2 expression in cultured primary hepatocytes was
reduced upon hypoxia inducible factor (HIF) stabilisation by dimethyloxalylglycine
(DMOG), demonstrating that HIFs are involved in the hypoxic downregulation of hepatic
Tdo2. DMOG abrogated hepatic luciferase signals in Tdo2 reporter mice, indicating that
HIF stability also recapitulates hypoxic rewiring of Trp metabolism in vivo. Also in WT mice
HIF stabilization drove homeostatic Trp metabolism away from the KP towards enhanced
tryptamine production, leading to enhanced levels of tryptamine in liver, serum and brain.
As tryptamines are the most potent hallucinogens known, the observed upregulation of
tryptamine in response to hypoxic exposure of hepatocytes may be involved in theorg February 2021 | Volume 12 | Article 5905321
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Frontiers in Immunology | www.frontiersin.generation of hallucinations occurring at high altitude. KP metabolites are known to
activate the aryl hydrocarbon receptor (AHR). The AHR-activating properties of
tryptamines may explain why immunosuppressive AHR activity is maintained under
hypoxia despite downregulation of the KP. In summary our results identify hypoxia as
an important factor controlling Trp metabolism in the liver with possible implications for
immunosuppressive AHR activation and mental disturbances.Keywords: liver, hypoxia, tryptophan, TDO2, regulation, AHR activity, hallucination, tryptamineINTRODUCTION
The liver and its role in the human physiology has intrigued
people for centuries (1). With advances in modern medicine and a
better understanding of human physiology, the liver has been
revealed as the central gatekeeper for all metabolic inputs, being
responsible for systemic metabolic homeostasis (1, 2). This master
regulator of metabolic inputs maintains steady state conditions
during times of plenty by metabolizing and channeling excessive
nutrients for storage, while during starved conditions the
previously stored nutrients are released for use by peripheral
tissues (2, 3). A class of nutrients that are acquired exclusively
through dietary sources are essential amino acids, for example Trp.
Dietary Trp upon absorption in the gut exists in the blood with a
majority bound to albumin while a minor fraction (5–10%) exists
as free Trp, with the existence of a rapid equilibrium between the
two (4). The liver regulates systemic free Trp levels by degrading
Trp into various metabolic products. Trp can be degraded along
three known minor metabolic pathways namely serotonin,
tryptamine and indolepyruvic acid pathways, however the liver
degrades a majority of dietary Trp through the KP (5, 6). To
accomplish this, hepatocytes endogenously express TDO2, which
catalyses the first step of the KP (7, 8).
In metabolically active tissues such as liver, oxygen availability
is an important factor not only for cell survival but also for
maintaining metabolic function as well as energy metabolism of
the cell (9). In the liver, cellular differentiation is also regulated by
oxygen availability both during liver development as well as liver
regeneration (10, 11). Cells exposed to hypoxic conditions
generally modulate the expression of a wide range of genes
through the upregulation of HIFs (12). Under normoxic
conditions, HIF proteins are degraded by prolyl-hydroxylase
(PHD) enzymes, however onset of hypoxia inhibits the action of
these enzymes thus stabilizing the HIF transcription factors, the
most prominent among which is HIF1a (13). Upon stabilization,
HIF1a translocates into the nucleus and modulates (i.e. both up-
or down-regulates) the expression of hypoxia target genes (9, 10).
Stabilization of HIF1a has also been reported in various hepatic
diseases such as hepatic ischemia reperfusion (IR) injury (14, 15),
alcohol-mediated liver injury (16), liver fibrosis (17), viral hepatitis
(18) as well as in hepatocellular carcinoma (19, 20).
We previously found that HIF1a downregulates the expression
of the Trp-catabolizing enzyme tryptophan-2,3-dioxygenase
(TDO2) in human glioblastoma cells (21). However, it is known
that the regulation of TDO2 differs between glioblastoma cells and
liver cells, indicating that TDO2 may be regulated in a tissue-org 2specific manner (22). Given the prevalence and importance of
hypoxia in hepatic development, as well as liver pathology, we
therefore set out to decipher the effects of hypoxia on Trp
catabolism in the liver. We report that hypoxia significantly
alters the homeostatic Trp catabolism in the liver by favouring
the production of tryptamine and its downstream metabolites,
instead of the usual KP metabolites.MATERIALS AND METHODS
Isolation of Primary Murine Hepatocytes
Isolation of primary hepatocytes from mice was approved under
the reference number A24/10 and G14/17 by the governmental
review committee on animal care of Baden-Württemberg,
Germany. C57BL/6N mice were obtained from Charles River
and housed at the DKFZ animal facility under a constant day
light cycle. Animals were allowed ad libitum access to a standard
mouse diet and water. Murine hepatocytes were harvested from
male animals aged between 8 to 10 weeks according to a
standardized protocol described earlier (23). Harvested
hepatocytes were seeded at a density of 1x106 cells/well, in 6
well collagen I-coated tissue culture plates (BD Biosciences), in 2
mL of adhesion medium and allowed to attach for 4 h at normoxic
conditions i.e. 18.6% O2 concentration (24) in a SANYO MCO-
18AIC incubator with 5%CO2 and at 37°C. The adhesion medium
consisted of phenol red-free Williams E medium (Biochrom)
containing 10% (v/v) fetal bovine serum (Life Technologies), 0.1
µM dexamethasone, 10 µg/mL insulin, 2 mM L-glutamine and 1%
(v/v) 100X penicillin/streptomycin (Life Technologies).
Following the 4 h of incubation, wells were washed twice with
PBS (Gibco) to remove unattached hepatocytes. This was followed
by an overnight incubation of the cells in serum-free medium. The
serum-free medium was composed of phenol red-free Williams E
medium containing 0.1 µM dexamethasone, 2 mM L-glutamine,
and 1% (v/v) 100X penicillin/streptomycin. Following the overnight
incubation, the serum-free medium was removed, cells were again
washed three times and 2 ml of serum and dexamethasone-free
mediumwas added for initiation of the hypoxia or hypoxia mimetic
treatments according to the respective experimental conditions
described in subsequent sections.
Hepatocytes Exposure to Low Oxygen
Conditions
Murine hepatocytes cultured in 6 well plates in serum and
dexamethasone-free medium were subjected to either normoxicFebruary 2021 | Volume 12 | Article 590532
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C42 was used to attain hypoxic conditions i.e. 1% O2
concentration with 5% CO2 and 37°C. Cells were always seeded
in duplicate for each time point with the control plate being
incubated in the normoxic incubator while the second was
incubated in the hypoxia incubator. Cells were lysed for RNA
extraction at the end of the respective time points.Treatment of Hepatocytes With
a Chemical HIF Protein Stabilizing Agent
The wel l known chemical mimetic of hypoxia i .e .
dimethyloxalylglycine (DMOG) was used for HIF protein
stabilization. 20M stocks of DMOG (Frontier Scientific Inc.)
were prepared in ethanol (Sigma). Hepatocytes were treated such
that they were exposed to 3 mM of DMOG in a well as final
treatment condition.RNA Isolation and Quantitative (q)RT-PCR
Total RNA was isolated from the harvested samples using a
Qiagen RNAeasy Mini Kit (Qiagen). Subsequently, a High
Capacity cDNA reverse transcriptase kit (Applied Biosystems)
was used for cDNA production from 1 µg total RNA. (q)RT-PCR
was performed using the SYBR Select Master Mix (Thermo Fisher
Scientific) on a StepOnePlus real-time PCR system (Applied
Biosystems). For all (q)RT-PCR measurements 18s Rna was
used as a housekeeping gene for normalization during analysis.
Unless stated otherwise, all the murine (q)RT-PCR primers for a
target gene used in the present study were designed using Primer
Blast (NCBI). The murine Ndrg1 primers used in the study were
taken from a prior publication by Okuda and colleagues (25). The
murine primer sequences used are listed below:Tdo2 Forward 5’- GAATGCGCAAGAACTTCAG -3’
Reverse 5’- TTCCAGAACCGAGAACTGCT -3’
18s Rna Forward 5’- GCAATTATTCCCCATGAACG -3’
Reverse 5’- GGCCTCACTAAACCATCCAA -3’
Ndrg1 Forward 5’- ACCCTGAGATGGTAGAGGGTCTC -3’
Reverse 5’- CCAATTTAGAATTGCATTCCACC -3’
Ddc Forward 5’- AGTAAGTTGCCCAAGCACCA -3’
Reverse 5’- ACGGGAATCCATGTTGAAAATTG -3’
Inmt Forward 5’- CTGGAGGGAGACAGAAGCAG -3’
Reverse 5’- ACACTCCATGGCCAGAAAGG -3’
Kyat1 Forward 5’- CCCCTGGGTGGAGTTTACCA -3’
Reverse 5’- GTGGAGGGTAACCAAACGCT -3’
Kynu Forward 5’- AAAAAGAGGAGTCGTTTGTGAC -3’
Reverse 5’- TGAAAACTCCATCACCTTTCAGTG-3’
Areg Forward 5’- GCTGAGGACAATGCAGGGTAA -3’
Reverse 5’- AGTGACAACTGGGCATCTGG-3’
Tiparp Forward 5’- TTGGAAATTCTTCTGTAGAGACCAC -3’
Reverse 5’- CTTCTTCAATTAGTCGAACAACAGAC -3’Frontiers in Immunology | www.froMetabolic Analysis of Trp and Its
Metabolites in Cultured Hepatocytes
by HPLC
For metabolic analysis, 1 ml cell culture supernatant from each
treatment was harvested and was snap frozen in liquid nitrogen.ntiersin.org 3Subsequently, the cells were harvested by trypsinization in 1.5 ml
PBS for intracellularmetabolicmeasurements.Tenmicroliterof cell
suspension were used for cell counting, while the rest were pelleted
for snap freezing in liquid nitrogen. The separated 10 µl of cell
suspension was mixed in a 1:1 ratio with Trypan Blue dye (Gibco)
and subsequently the cell count was measured using an automated
Cell Counter (Countess, Invitrogen). Intracellular metabolite
extraction was performed with 0.1 ml 6% perchloric acid per
million cells in an ultrasonic ice-bath for 10 min. Supernatants
weremixed in a 1:1 ratiowith 12%perchloric acid and incubated on
ice for 10min. Subsequently samples were centrifuged atmaximum
speed and 4°C to remove remaining cell debris. Separation was
achieved on an Acquity H-class UPLC system (Waters) using an
AcquityHSST3column(100×2.1mm,1.7 µm,Waters),whichwas
maintained at 37°C. Clear separation of Trp and Trp downstream
metaboliteswas achieved by increasing the concentration of solvent
B (Acetonitrile) in solvent A (20 mM sodium acetate, 3 mM zinc
acetate, pH 6). An Acquity FLR detector (Waters) was used for
detecting Trp, 3-hydroxyanthranilic acid (3HAA), kynurenic acid
(KynA) and tryptamine by fluorescence (excitation: 254 nm,
emission: 401 nm). While for kynurenine (Kyn) and 3-hydroxy-
kynurenine (3HKyn) an Acquity PDA detector (Waters) was used
for measuring absorption at 365 nm. UPLC grade standards
(Sigma) were used for quantification of all analytes. The
Empower3 software suite (Waters) was used for data acquisition
and processing.
DMOG Treatment for Metabolic
Measurements in WT C57BL/6 Mice
Ten week old male WT C57BL/6 mice were obtained from Charles
River and housed at the DKFZ under a constant day light cycle.
Three mice each were injected i.p. either with saline control (0.9%
NaCl) (Fresenius Kabi) or with 8 mg/mouse DMOG (Echelon
Biosciences) dissolved in saline (0.9% NaCl) (Fresenius Kabi).
Twenty-four hours post treatment, the animals were sacrificed for
collection of blood serum and tissue samples from liver and brain
for metabolic analysis of the Trp metabolic products kynurenine
and tryptamine. The experiments were approved under the animal
grant number G240/18 by the governmental review committee on
animal care of Baden-Württemberg, Germany.
LC-MS/MS Based Metabolic Analysis
of Trp and Its Metabolites in Frozen
Tissue and Serum
Frozen liver and brain tissue was processed following an adjusted
extraction protocol targeting tryptophan and kynurenine
metabolites (26, 27). Briefly, samples were crushed using a ball
mill (MM400, Retsch) with liquid nitrogen cooled beakers and
stainless-steel balls for 1 min (brain) and 1.50 min (liver) at its
highest frequency (30 Hz). The samples were then weighed for
later normalization and subsequently mixed with 100 µl acidified
mobile phase (0.2% formic acid + 1% acetonitrile in H2O) and
400 µl ice cold methanol.
Similarly, 15 µl of plasma was mixed with 35 µl of acidified
mobile phase and 200 µl of methanol. Afterwards, all samples
were kept at −20°C for 30 min to precipitate all protein.February 2021 | Volume 12 | Article 590532
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16.400 g and the resulting supernatant was transferred to a new
1.5 ml microcentrifuge tube (Eppendorf). Finally, the
supernatant was dried using the Eppendorf Concentrator Plus
set to no heat and resuspended in 40 µl acidified mobile phase.
For metabolite separation and detection, an Acquity I-class Plus
UPLC system (Waters) coupled to an QTRAP 6500+ (SCIEX) mass
spectrometer with electrospray ionization (ESI) source was used. In
detail, metabolites were separated by reversed phase
chromatography on an Acquity HSS T3 column (150 mm x
2.1 mm, 1.7 µm, Waters) kept at 20°C and a flow rate of 0.4 ml/
min. An overview of multiple reaction monitoring (MRM)
transitions that were used can be found in Table S1. Clear
separation of tryptophan and tryptophan-derived compounds was
achieved by increasing the concentration of solvent B (Acetonitrile
+ 0,1% formic acid) in solvent A (H2O + 0.1% formic acid) as
follows: 1 min 5% B, 11 min 40% B, 13 min 95% B, 15 min 95% B,
and return to 5% B in 5 min. Data acquisition and processing was
performed with the Sciex OS software suite (SCIEX).
Microarray Analysis
One hundred nanogram total RNA was used for generating
labeled ss-cDNA using an Affymetrix WT PLUS Reagent Kit.
The Affymetrix Mouse Gene 2.0 ST chip was used for
hybridization of 5.5 µg fragmented and labeled ss-cDNA for
17 h at 45°C. In accordance to the GeneChip R Expression
Wash, Stain and Scan Manual for Cartridge Arrays (P/N702731)
an Affymetrix GeneChip R Scanner 3000 was used for scanning
the hybridized chips. The Raw CEL files were imported from disk
followed by RMA normalization and summarization using the
oligo package and were annotated at the probeset level using
NetAffx (28). Differential gene expression was conducted by fitting
linear model and estimating a moderated t-statistic followed by
eBayes adjustment as described in the limma package (29, 30). All
analyses were run in R, version 3.4.4, (https://cran.r-project.org/)
and Bioconductor version 3.6 (https://bioconductor.org/). All
graphical representations were generated using ggplot2, ggpubr,
and RcolorBrewer. All datasets generated during the current study,
have been made publicly available in the Gene Expression
Omnibus (GEO) repository under accession number GSE159320.
Mathematical Modelling of Trp Metabolism
To simulate Trp metabolism in murine hepatocytes, we used the
mathematical model of Trp metabolism previously published by
Stavrum et al. (31). Expression data generated for murine
hepatocytes exposed to normoxia or hypoxia for 48 h were
integrated into the model as described in Schäuble et al. (32)
and COPASI 4.28 (33) was used to calculate the steady state
concentrations and fluxes. The concentration of extracellular Trp
was set to 10 mM, corresponding to the upper bound of free Trp
concentrations measured in blood (34).
Bioluminescence Measurement
in Reporter-TDO2 Mice
The mouse line was developed and previously described by Lanz
et al. (35). Homozygous reporter-TDO2 were injected with 50 mg/
kg d-luciferin (StayBrite™, BioVision, Mountain View, CA, USA)Frontiers in Immunology | www.frontiersin.org 45 min before imaging. The reporter mice were anaesthetized using
isoflurane and assayed for bioluminescence intensity using an in
vivo Imaging System (IVIS, Caliper/PerkinElmer, Waltham, MA,
USA) with a cooled charged-coupled device (CCD) camera.
Following baseline imaging prior to treatment, three mice each
were injected i.p. with 8 mg/mouse DMOG (Frontier Scientific Inc.)
dissolved in saline (0.9% NaCl) (Fresenius Kabi), following which a
second bioluminescence imaging was performed 24 h later.
Bioluminescence images were acquired as photons/s/cm2/
steradian over a period of 60 s using the Living Image software
(version 2.50, Caliper/PerkinElmer). Signal quantification was done
by measuring emitted photons from acquisition regions.
Bioluminescence was plotted as fold change compared to pre-
treatment baseline levels. The experiments were approved under
the animal grant number G240/18 by the governmental review
committee on animal care of Baden-Württemberg, Germany.
Statistical Analysis
GraphPad Prism v8.02.1 (GraphPad Software Inc.) was used for
statistical analysis. For single comparisons between two data sets,
unpaired two-tailed Student’s t-tests were utilized. Rank sum
analysis by Mann-Whitney U test was carried out wherever
necessary. All data are plotted as mean (± SEM), unless stated
otherwise. Differences with a p ≤ 0.05 were considered to be
statistically significant (ns non significant; p > 0.05; * p ≤ 0.05;




Microarray analysis of mRNA expression in cultured primary
murine hepatocytes post exposure to 48 h of hypoxia (1% O2),
revealed a strong reduction in the expression of Tdo2 mRNA
(Figure 1A). Establishment of intra-cellular hypoxia was
confirmed by increased expression of the surrogate hypoxia
marker Ndrg1 and also upregulation of the Hallmark_Hypoxia
pathway genes (Figure 1B). The results of the microarray were
validated by (q)RT-PCRmeasurements (Figures 1C, D) not only at
48 h but also across all measured time points. The measurements
revealed elevated Ndrg1 mRNA levels (Figure 1C) in hypoxic
hepatocytes, while constitutive Tdo2 mRNA expression was
reduced across all time points (Figure 1D). These observations
are in line with our prior observations in glioblastoma cells,
indicating that downregulation of TDO2 might be a global
response to hypoxia.
Hypoxia Mediated Tdo2 Downregulation
in Hepatocytes Reduces Trp Flux
In light of the hypoxia-mediated downregulation of Tdo2
expression, we next conducted an in silico analysis to study the
global effects of hypoxia on Trp metabolism in hepatocytes.
Microarray-based RNA expression data of Trp pathway enzymes
and transporters, together with other predefined modelling
parameters were fed into a previously described Trp metabolismFebruary 2021 | Volume 12 | Article 590532
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decrease in the Trp-Kyn exchange by the well-studied large amino
acid transporters LAT1 (SLC7A5) and LAT2 (SLC7A8) is observed
(Figure 2A). Further, hypoxia also reduced hepatic Trp flux through
TDO2 into the KP, which in turn decreased the metabolic flux
through downstream KP enzymes such as kynureninase (KYNU),
kynurenine aminotransferases (KATs), kynurenine 3-
monooxygenase (KMO) (Figure 2B). Enzymatic flux was also
reduced under hypoxia further downstream in the KP such as
through the enzymes hydroxyanthranilic acid oxidase (HAAO)
and quinolinic acid phosphoribosyltransferase (QPRT) i.e. the
enzymes that feed into the de novo NAD synthesis pathway
(Figure 2B). In contrast, flux through the serotonin synthesis
pathway catalyzed by tryptophan hydroxylase 1 (TPH1)
(Figure 2B) showed a tendency towards an increase.
Interestingly, inspite of the reduced flux of Trp into the
hepatocytes under hypoxia, there was an increased flux of Trp
through dopa decarboxylase (DDC), which converts Trp to
tryptamine and subsequently also through indolethylamine
methyltransferase (INMT), which further methylates tryptamine
tomethyltryptamine and dimethyltryptamine (DMT) (Figure 2B).
These results indicate that reduced oxygen availability reduces TrpFrontiers in Immunology | www.frontiersin.org 5metabolism down the KP, while promoting the production of
tryptamine and its downstream metabolites.
Gene expression analysis by microarray revealed that the
expression of TDO2 and other KP enzymes was reduced under
hypoxic exposure, while expression of non-KP enzymes such as
INMT was increased upon reduced oxygen availability (Figure 3A),
which was confirmed by qRT-PCR analysis (Figures 3B–G).
Measurement of Intra-Cellular Trp Derived
Metabolites Validate the In Silico Analysis
Next using the aforementioned Trp model, we carried out in silico
predictions which depicted reduced KP metabolite concentrations
downstream of TDO2 (blue plots, Figures 4A–E). The increased
flux through DDC as observed earlier in Figure 2B, was also
reflected in the simulated tryptamine concentration (blue plot,
Figure 4F). These modelling results are indicative of the possibility
of an extensive reprogramming of Trp metabolism in hepatocytes
upon exposure to hypoxia. To verify these in silico predictions, we
next performed metabolic analysis of the hepatocytes cultured
under hypoxic conditions for 48 h, which revealed a diminished
intracellular Trp pool under hypoxia (black plot, Figure 4A),
which is in line with the predicted reduction in Trp uptake byA B
DC
FIGURE 1 | Tryptophan-2,3-dioxygenase (Tdo2) expression is reduced in primary murine hepatocytes exposed to hypoxia. (A) Volcano plot showing the
differentially regulated genes in microarray data of primary murine hepatocytes after exposure to 48 h hypoxia (1% O2) compared to control hepatocytes exposed to
48 h normoxia (19% O2). (n=3) (B) Differentially regulated top 10 hallmark pathways enriched in the microarray data shown in (A). (C) mRNA expression of the
surrogate hypoxia marker gene Ndrg1 measured by (q)RT-PCR in primary murine hepatocytes after 1, 2 or 3 days of exposure to either normoxia (white) or hypoxia
(back). (n=3) (D) Expression of Tdo2 mRNA measured by (q)RT-PCR in primary murine hepatocytes as in (C). Data represented as mean ± S.E.M. Statistical
significance was assumed at p < 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001).February 2021 | Volume 12 | Article 590532
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Kyn (black plot, Figure 4B), 3HAA (black plot, Figure 4C) and
KynA (black plot, Figure 4D) were also significantly reduced in
hepatocytes exposed to oxygen restricted conditions.
The quinolinic acid levels measured in hypoxic hepatocytes were
also decreased (black plot, Figure 4E), validating the predictedFrontiers in Immunology | www.frontiersin.org 6reduction in quinolinic acid (blue plot, Figure 4E). This hypoxia
induced decrease in quinolinic acid, a precursor required for de novo
NAD synthesis, resulted in reduced abudance of NAD, NADH,
NADPH as well as other energy currencies in the hepatocytes
(Figure S1A–S1E). Of note, in line with the prediction of increased
tryptamine levels under hypoxia (blue plot, Figure 4F), aFIGURE 2 | Reduced Tdo2 expression leads to reduced Trp flux through the kynurenine pathway (KP). (A) Predicted flux through the large amino acid transporters
SLC7A5 and SLC7A8 in hepatocytes under hypoxia (maroon bars) as compared to control normoxic hepatocytes (white bars). The abbreviations used for the
transporters are SLC7A5—large neutral amino acids transporter small subunit 1 (LAT1) and SLC7A8—large neutral amino acids transporter small subunit 2 (LAT2).
ECM – extracellular matrix (n=3). (B) Graphical depiction of the changes in the flux through the different enzymes involved in the Trp metabolic pathway upon exposure to
either normoxia (white bars) or hypoxia (blue bars). Microarray data generated from primary murine hepatocytes exposed to either 48 h hypoxia or normoxia as described
in Figure 1A, was integrated into a mathematical model of Trp metabolism to calculate the fluxes through the different enzymes. (n=3) The abbreviations used for the
enzyme names are DDC: dopa decarboxylase; TPH1: L-tryptophan hydroxylase 1; IL4I1: interleukin 4 induced 1; INMT: indolethylamine methyltransferase; KATs:
kynurenine aminotransferases; KYNU: kynureninase; KMO: kynurenine 3-monooxygenase; HAAO: hydroxyanthranilic acid oxidase and QPRT: quinolinic acid
phosphoribosyltransferase. Data represented as mean ± S.E.M. Statistical significance is assumed at p < 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001). ns, not significant.February 2021 | Volume 12 | Article 590532
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inside hypoxic hepatocytes (black plot, Figure 4F). Taken together,
these metabolic measurements validate the results of the Trp
metabolic model and demonstrate that in hepatocytes hypoxic
exposure restricts the KP, while simultaneously channeling Trp
towards tryptamine production.HIF Stabilization Reduces Tdo2
Expression in Mouse Liver
A majority of the cellular effects of hypoxia are known to be
mediated by stabilization of the HIF master regulators. Therefore,
we next explored if HIFs also regulate the metabolic fate of Trp in
hepatocytes. To this end, we employed the well-known chemical
hypoxia mimetic dimethyloxalylglycine (DMOG), which acts by
inhibiting the prolyl-hydroxylase enzymes and thus stabilizes the
HIF proteins even under sufficient oxygen availability. Upon
exposure to DMOG, cultured primary mouse hepatocytes
significantly upregulated the HIF-controlled hypoxia response
gene Ndrg1 (Figure 5A), while simultaneously downregulating
the expression of Tdo2 (Figure 5B).
To explore whether the downregulation of Tdo2 upon HIF
stabilisation also occurs in vivo, we utilised Tdo2 reporter mice (35).
In these mice, the Tdo2 gene sequence has been switched with a
luciferase gene, which is still under the regulatory control of the
Tdo2 promoter, thus enabling the study of Tdo2 gene expression inFrontiers in Immunology | www.frontiersin.org 7vivo. For the current study, these mice were subjected to an initial
baseline bioluminescence measurement (Figure 5C, left)
immediately before treatment with DMOG. Twenty-four hours
post DMOG treatment, a second bioluminescence measurement
was performed. The bioluminescence signal intensity was strongly
reduced after DMOG treatment (Figure 5C, right) as compared to
the baseline measurement. Quantification of the bioluminescence
revealed a significant reduction in signal intensity in response to
DMOG (Figure 5D), which signifies less expression of Tdo2.
We next investigated the HIF-induced changes in Trp
homeostasis in vivo. Metabolic measurements revealed that after
24 h of DMOG treatment the Kyn levels in the livers of the mice were
significantly reduced, while a trend towards reduced Kyn levels was
observed in the serum and the brain tissue of the mice (Figures 5E–
G). Of note, significantly elevated levels of tryptamine were measured
in the liver, serum and brain of DMOG treated mice (Figures 5E–G).
Taken together these results show that HIF stabilization in vivo results
in an increased production of tryptamines, while simultaneously
reducing KP metabolites (Figure 5H).
Maintainance of Hepatic AHR Activation
Under Hypoxia
Many reports associate the AHR with Trp metabolite dependent
cellular effects (36). We therefore hypothesized that the reduced
production of Kyn and downstreammetabolites under hypoxia could
potentially reduce AHR activity in the hepatocytes. To check theA B
D E F G
C
FIGURE 3 | Trp transporters and other Trp pathway enzymes are differentially regulated by hypoxia. (A) Heatmap depicting microarray data as in Figure 1A used
for generating the Trp metablic model, showing the differential regulation of mRNA expression of Trp pathway enzymes and Trp transporters under hypoxia. (n=3)
(B–G) Expression of Trp pathway enzymes mRNA measured by (q)RT-PCR validating the microarray data for expression of (B) Tdo2, (C) Kmo, (D) Kynu, (E) Kyat1,
(F) Ddc, (G) Inmt. (n=3) Data represented as mean ± S.E.M. Statistical significance is assumed at p < 0.05 (**p < 0.01, ***p < 0.001, ****p ≤ 0.0001).February 2021 | Volume 12 | Article 590532
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expression data generated by the microarray in Figure 1A. The top
table (Table S2) revealed the upregulation of many well-known AHR
target genes (listed in Table 1). Furthermore, bioinformatics analysis
of the data also revealed genes in the Reactome_Xenobiotics pathway
to be one of the top 10 upregulated curated pathways in hypoxic
hepatocytes (Figure S2A).
Previous studies reported tryptamine-mediated AHR
activation (47). We therefore hypothesized that the observed
AHR activity under hypoxia could be attributed to the increased
tryptamine levels. To test this hypothesis, we treated murine
hepatocytes with tryptamine. Tryptamine treatment induced theFrontiers in Immunology | www.frontiersin.org 8mRNA expression levels of the two well-known AHR target
genes Areg and Tiparp (Figures S2B, S2C), suggesting that
tryptamine increases AHR activity upon accumulation. Taken
together, these observations are indicative of maintainance of
AHR-mediated transcriptional activity in hypoxic hepatocytes
even upon reduced KP metabolite production.
DISCUSSION
In the human body, the liver is at the very core of a range of
systemically important processes such as digestion, nutrient




FIGURE 4 | Mathematical modelling and uHPLC measurements predicts a complete rewiring of hepatic Trp catabolism under hypoxia. Using the microarray data as
described in Figure 2, the model predicts the intracellular metabolite concentrations in primary murine hepatocytes exposed to normoxia (white bars) or hypoxia
(blue bars) for 48 h (n=3). uHPLC measurements of intracellular metabolite concentrations of hepatocytes cultured for 48 h either under normoxia (white bars) or
hypoxia (black bars) (n=3). These plots reveal intracellular predictions for changes in concentration and actual measured intracellular concentrations of various Trp
metabolic products (A) tryptophan (Trp), (B) kynurenine (Kyn), (C) 3-hydroxyanthranilic acid (3HAA), (D) kynurenic acid (KynA), (E) quinolinic acid (Quin) and
(F) tryptamine (Trypta). The external Trp concentration is kept constant and is fed as an input into the model thus predictions for Trp changes are not available, while
the model lacks sufficient enzymatic parameters for KynA change predictions therefore the respective plots indicate n.a., not available. Data represented as mean ±
S.E.M. Statistical significance is assumed at p < 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001, ****p ≤ 0.0001). n.d. - not detected/below detection limit.February 2021 | Volume 12 | Article 590532
Mohapatra et al. Hypoxia Effects on Hepatic Tdo2of systemic nutrient availability and metabolism (1, 3, 48). Trp
catabolism represents one such systemically important process,
in which the liver plays a central role (4). Many ailments of the
liver as well as circulatory and pulmonary systems can adversely
impact hepatic blood flow and oxygen availability, thus resulting
in portal hypoxemia and subsequent hepatic hypoxia (49, 50).
Occurrence of hepatic hypoxia can impair hepatic functionality
and thus adversely affect systemic metabolic homeostasis. Recent
reports have highlighted hypoxia-mediated changes in the
expression of hepatic glucose and lipid metabolic pathway
genes resulting in altered liver metabolism (3, 51, 52).
In light of the aforementioned reports and given the
importance of the liver in systemic Trp metabolism, we
explored the effects of hypoxia on hepatic Trp homeostasis.
Our results indicated that under hypoxia, murine hepatocytes
downregulated the expression of Tdo2 (Figure 1). MicroarrayFrontiers in Immunology | www.frontiersin.org 9analysis and qRT-PCR analyses also revealed differential
expression of different Trp pathway transporters and enzymes
under exposure to oxygen limiting conditions (Figure 3). The
discovery of this regulatory effect aroused our curiosity regarding
the effect of hypoxia on the production of different Trp
metabolites both dependent as well as independent of TDO2.
Modelling of Trp metabolism as well as metabolic measurements
showed that hypoxia significantly reduced the flow of Trp into
the KP, thus resulting in the reduced production of KP
metabolites such as Kyn, KynA, 3HAA and QA (Figures 2 and
4), many of whom play a role in systemically important processes
such as immune modulation, neuro-transmission and are also
precursor feeder molecules into other metabolic pathways such
as the de-novo NAD synthesis pathway. Furthermore, our
experiments also revealed the simultaneous channeling of Trp
metabolism towards non-KP pathways under hypoxia. In line,A B
D E F G
H
C
FIGURE 5 | HIF stabilization suppresses hepatic Tdo2 expression, resulting in elevated tryptamine levels in the liver, serum and brain. (A) mRNA expression analysis
of Ndrg1 by (q)RT-PCR in primary murine hepatocytes upon HIF stabilization by exposure to 3 mM DMOG for 24 h. (n=4) (B) Expression of Tdo2 mRNA in primary
murine hepatocytes after treatment with 3 mM of the HIF-stabilizing agent, DMOG for 24 h. (n=4) (C) IVIS image of 6 weeks old Tdo2 reporter mice at baseline pre
DMOG treatment (left) and 24 h post DMOG treatment (right). (D) Quantification of the bioluminescence signal measured by IVIS (n=3). (E–G) LC-MS/MS based
measurements of kynurenine and tryptamine levels in (E) liver tissue, (F) serum and (G) brain tissue of WT C57BL/6 mice treated with saline control (white bars) or
8 mg/mouse DMOG (black bars) for 24 h (n=3). (H) Graphical summary depicting increased tryptamine and decreased kynurenine production in liver under hypoxic
stress, due to reduced TDO2 expression. Data are expressed as mean ± S.E.M. Statistical significance is assumed at p < 0.05 (*p < 0.05, **p < 0.01, ****p ≤
0.0001). ns, not significant.February 2021 | Volume 12 | Article 590532
Mohapatra et al. Hypoxia Effects on Hepatic Tdo2increased Trp flux through the non-KP enzyme DDC
(Figure 2B) led to increased production of the Trp metabolite
tryptamine (Figure 4F) in liver hepatocytes. Previous reports of
elevated tryptamine levels in patients with hypoxic liver cirrhosis
(53) and in rat models of chronic ischemic tissue hypoxia (54)
are consistent with our findings. Taken together, the previous
reports and our current findings, establish the presence of
extensively remodelled Trp metabolic pathways in the liver
under pathological as well as induced hypoxic conditions,
which favours increased production of tryptamine.
Tryptamine is a trace amine and it lends its name to a broad class
of serotonergic hallucinogens or psychedelic compounds, long
known to induce episodes of psychosis, hallucinations or altered
states of consciousness (55, 56). Tryptamine and its downstream
hallucinogenic metabolites including DMT are found endogenously
in mammalian brain although in trace amounts (57, 58). A two step
methylation of tryptamine, catalysed by indolethylamine
methyltransferase (INMT), first gives rise to methyl-tryptamine
and subsequently DMT (59). Our in silico data showed a
significantly increased flux through INMT under hypoxic
conditions (Figure 2B), which could potentially lead to increased
methyl-tryptamine and DMT levels. Numerous reports indicate the
occurrence of altered states of consciousness among non-
acclimatized high altitude climbers and hikers (47, 60–63). Apart
from the reduced oxygen availability to the brain, our current results
(Figures 4F and 5E–G) suggest that such experiences could be
caused by increased levels of endogenous psychedelic compounds
such as tryptamine and DMT. Furthermore, abnormal behavioural
patterns are also common in hepatic encephalopathy, where prior
studies have reported enhanced levels of endogenous tryptaminesFrontiers in Immunology | www.frontiersin.org 10(53, 64–67), which could now be attributed to the widespread
prevalence of hypoxia in the diseased liver. In addition, increased
levels of DMT can potentially constitute a feedback protection
mechanism against hypoxic injury via the Sigma-1 receptor,
through decreased expression of the master hypoxic transcription
regulator HIF protein (58).
The liver plays an important role in systemic immune tolerance,
as its specially configured microenvironment hosts a repertoire of
antigen presenting cells (APCs), which promotes tolerance against a
range of harmless antigens often found in the diet (68, 69).
These resident APCs enforce immunosuppression by production
of anti-inflammatory cytokines and expression of programmed cell
death ligand 1 (PD-L1) (70). Furthermore, hepatic resident
APCs such as Kupffer cells are also known to employ the
immunosuppressive effects of Trp catabolism in response to an
inflammatory stimulus (71). The immunosuppressive effects of Trp
catabolism can be mediated by a two-pronged strategy, first by
depletion of Trp, as Trp is essential for the proliferation and activity
of liver-infiltrating T cells (72, 73) and secondly by the AHR-
mediated immunosuppressive action of the KP metabolites, as has
frequently been described in extra-hepatic systems such as the
placenta (74) and different types of cancers (36, 75, 76).
Mindful of the role of AHR in immune tolerance, the observed
hypoxic suppression of KP metabolite production could potentially
affect hepatic AHR activation and thus hamper the immunological
balance of the hepatic microenvironment. However, to our surprise,
we found several well-known AHR target genes as well as the
Reactome_Xenobiotics pathway upregulated in hypoxic hepatocytes
(Tables 1, S2 and Figure S2A). Our experimental results revealed
that accumulation of tryptamine can potentially maintain AHR
activity (Figures S2B, S2C). Apart from the previously discussed
psychedelic effects of tryptamine, both endogenous tryptamine as
well as tryptamine of gut microbial origin have been reported to
posses immune-modulatory effects mediated via AHR activation
(47, 60–63). Together, previous reports as well as data from the
current study clearly indicate towards the effective maintainance of
essential immunosuppresive AHR activation in hepatic cells
exposed to hypoxia, which could be attributed to increased
production and accumulation of other non-KP Trp metabolites
such as tryptamine.
In summary, our results demonstrate the conservation of HIF-
mediated suppression of Trp catabolism along the KP both in
malignant as well as primary cells constitutively expressing TDO2,
which illustrates the significance of this mechanism not only in
pathology but also in normal physiology. In the liver cells, this
suppression leads to the complete re-wiring of the Trp metabolic
pathways favouring the tryptamine branch. However, the increase
in tryptamine generated through DDC, the only Trp-metabolizing
enzyme which does not require oxygen, appears to be specific for
hepatocytes as an increase in tryptamine was not observed in
hypoxic glioblastoma cells (21). This channeling of Trp into
tryptamine and its downstream metabolites methyl-tryptamine
and DMT could explain the “out of the body” experiences
reported under oxygen-limited conditions. Furthermore, the
hypoxic upregulation of the tryptamine branch of Trp











1 Cyp2e1 11.179 8.725 2.86E-09 1.24E-05 (37)
2 Cyp4a12a 10.241 7.111 2.48E-06 0.000165 (37)
3 Cyp2s1 7.771 6.703 4.73E-05 0.000889 (38)
4 Cyp1a2 6.555 8.567 3.88E-07 6.82E-05 (37)
5 Cyp17a1 5.644 6.373 6.88E-05 0.001092 (39)
6 Cyp3a11 5.348 8.928 2.37E-05 0.000577 (40)
7 Areg 5.314 6.434 1.56E-05 0.000461 (41)
8 Cyp2c54 5.174 6.974 0.000108 0.00144 (42)
9 Cyp2f2 5.095 9.577 2.23E-08 1.48E-05 (38)
10 Ces2a 4.372 8.393 2.41E-07 5.03E-05 (42)
11 Cyp51 4.264 8.083 8.50E-07 9.98E-05 (43)
12 Cyp3a16 4.218 8.578 5.78E-05 0.001001 (38)
13 Cyp3a41b 3.110 7.323 0.000117 0.001537 (44)
14 Tiparp 2.587 7.120 0.000166 0.00189 (45)
15 Gsn 2.576 7.330 5.71E-05 0.000993 (46)
16 Aldh3a1 2.221 7.100 0.001105 0.00648 (38)The microarray data shown in Figure 1A was used for this analysis. For generating this
table a fold change cut-off of 2 was considered. The fold change, average expression, p
values and the references showing that the genes are AHR target genes are indicated. The
data was generated from at least three independent experiments using primary murine
hepatocytes cultured in vitro for 48 h exposed to hypoxia (1% O2) and compared to control
primary murine hepatocytes cultured under 48 h normoxia (19% O2) conditions. For the
complete list of all upregulated genes with a fold change ≥ 2 refer to Table S2.February 2021 | Volume 12 | Article 590532
Mohapatra et al. Hypoxia Effects on Hepatic Tdo2of immunosuppresive AHR activation despite the suppression of
the KP branch of Trp catabolism.DATA AVAILABILITY STATEMENT
The datasets generated during this study are available publicly in
the Gene Expression Omnibus 429 (GEO) repository under
accession number GSE159320.ETHICS STATEMENT
The animal studywas reviewed and approved by Regierungspräsidium,
Karlsruhe, Germany.AUTHOR CONTRIBUTIONS
SM and CO designed the study. SM, GP, and CO developed
methodology. PL and UK isolated primary murine hepatocytes.
TL and MP developed and provided Tdo2 reporter mice. SM,
HG, and GP acquired data. SM, AS, SS, GP, HG, IH, and CO
analyzed and interpreted data. SM and COwrote the manuscript.
All authors contributed to the article and approved the
submitted version.FUNDING
This work was supported by grants from the BMBF e:Med
initiative (GlioPATH, 01ZX1402), the European Union’s
Horizon 2020 research and innovation programme under
Grant 754688 (MESI-STRAT), DFG grant 406052676, PL-315/
5-1 and the Liver Systems Medicine network (LiSyM, 031L0042).Frontiers in Immunology | www.frontiersin.org 11ACKNOWLEDGMENTS
We thank the Microarray Unit of the DKFZ Genomics and
Proteomics Core Facility for excellent services. We thank Dr.
Artyom Vlasov, Ina Schmitt, Sandra Bonefas, and Lena Postawa
for isolation of primary hepatocytes.SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.
590532/full#supplementary-material
Supplementary Figure 1 | Hypoxia downregulates cellular energetics in cultured
murine hepatocytes. LC-MS/MS measurements of intracellular energy currencies in
hepatocytes cultured for 48 h either under normoxia (white bars) or hypoxia (black
bars) (n=4). These plots reveal intracellular concentrations of (A) nicotinamide
adenine dinucleotide (NAD), (B) reduced NAD (NADH), (C) reduced nicotinamide
adenine dinucleotide phosphate (NADPH), (D) adenosine diphosphate (ADP) and
(E) adenosine triphosphate (ATP) Data represented as mean ± S.E.M. Statistical
significance is assumed at p < 0.05 (*p < 0.05, **p < 0.01, ***p <0.001, ****p ≤
0.0001). n.d. - not detected/below detection limit.
Supplementary Figure 2 | (A) Top 20 differentially enriched curated pathways,
with top 10 up-regulated (orange) and top 10 down-regulated (green) pathways in
the microarray data shown in Figure 1A. The data was generated from at least
three independent experiments using primary murine hepatocytes after exposure to
48 h hypoxia (1% O2) compared to control hepatocytes exposed to 48 h normoxia
(19%O2). (B) Analysis of AHR activation upon treatment of murine hepatocytes with
tryptamine by (q)RT-PCR based mRNA expression analysis of the AHR target gene
Areg (n=3) (C). AHR activity test as described in B by (q)RT-PCR based mRNA
expression analysis of the AHR target gene Tiparp (n=3) Data are expressed as
mean ± S.E.M. Statistical significance is assumed at p < 0.05 (*p < 0.05, **p < 0.01,
****p ≤ 0.0001).
Supplementary Table 2 | Complete list of all upregulated genes in hypoxic
primary murine hepatocytes with a fold change ≥ 2.REFERENCES
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